Safety and Tolerability of Sequential Pegylated IFN-α2a and Tenofovir for Hepatitis B Infection in HIV+ Individuals

REFERENCES

• Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the Inter-national AIDS Society-USA panel. JAMA. 2006;296(7): 827–843.
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recom-mendations from an HIV-HBV International Panel. AIDS. 2005;19(3):221–240.
   PubMed Web of Science ®Google Scholar
• Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis. 2006;43(7):904–910.
   PubMed Web of Science ®Google Scholar
• Shire NJ, Sherman KE. Management of HBV/HIV-coinfected patients. Semin Liver Dis. 2005;25\(suppl 1):48–57.
   PubMed Web of Science ®Google Scholar
• Thio CL, Sulkowski MS, Thomas DL. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis. 2005;41(7):1035–1040.
   PubMed Web of Science ®Google Scholar
• Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J HepatoL 2006;44S1 :S90–S94.
   Google Scholar
• Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis. 2004;8(2):255–266.
   PubMedGoogle Scholar
• Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921–1926.
   Web of Science ®Google Scholar
• De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regi-mens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162(18):2125–2132.
   PubMed Web of Science ®Google Scholar
• Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiret-roviral therapy. HIV Med. 2003;4(3):241–249.
   PubMedGoogle Scholar
• Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT co-hort. AIDS. 2004;18(8):1169–1177.
   PubMed Web of Science ®Google Scholar
• Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571–577.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19(18):2117–2125.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J HepatoL 2005;42(6):799–805.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in pa-tients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18(15):2039–2045.
   Web of Science ®Google Scholar
• Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepa-titis B in homosexual men. Hepatology. 1999;29(4)1 306–1310.
   Web of Science ®Google Scholar
• Gilson RJ, Hawkins AE, Beecham MR, et al. Interac-tions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11(5):597–606.
   PubMed Web of Science ®Google Scholar
• Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterol-ogy. 2002;123(6):1812–1822.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular car-cinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-in-fected patients. Hepatology. 2006;43(3):548–555.
   PubMed Web of Science ®Google Scholar
• Nunez M, Ramos B, Diaz-Pollan B, et al. Virological out-come of chronic hepatitis B virus infection in HIV-coin-fected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retro viruses. 2006;22(9):842–848.
   PubMed Web of Science ®Google Scholar
• Peters MG, Andersen J, Lynch P, et al. Randomized con-trolled study of tenofovir and adefovir in chronic hepati-tis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44(5):1110–1116.
   PubMed Web of Science ®Google Scholar
• Schmutz G, Nelson M, Lutz T, et al. Combination of te-nofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 2006;20(15):1951–1954.
   Web of Science ®Google Scholar
• Jain MK, Comanor L, White C, et al. Treatment of hepati-tis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat. 2007;14(3)1 76–182.
   Web of Science ®Google Scholar
• Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepa-titis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS. 2005;19(9):907–915.
   PubMed Web of Science ®Google Scholar
• Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunode-ficiency virus. J Antimicrob Chemother 2005;56(6):1087–1093.
   PubMed Web of Science ®Google Scholar
• Nelson M, Portsmouth S, Stebbing J, et al. An open-la-bel study of tenofovir in HIV-1 and hepatitis B virus co-in-fected individuals. AIDS. 2003;17(1):F7–10.
   PubMed Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10(6):727–734.
   PubMed Web of Science ®Google Scholar
• Wong DK, Yim C, Naylor CD, et al. Interferon alfa treat-ment of chronic hepatitis B: randomized trial in a predomi-nantly homosexual male population. Gastroenterology. 1995;108(1):165–171.
   PubMed Web of Science ®Google Scholar
• McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B vi-rus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology. 1987;7(4):719–723.
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–2695.
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451–459.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Pe-ginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–450.
   PubMed Web of Science ®Google Scholar
• Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete vi-rus suppression taking tenofovir and didanosine. AIDS. 2005;19(6):569–575.
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized con-trolled trial. JAMA. 2004;292(23):2839–2848.
   PubMed Web of Science ®Google Scholar
• Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract. 2006;60(2):201–211.
   PubMed Web of Science ®Google Scholar
• Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepa-tology. 2000;32(4 pt 1):803–806.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37(4):748–755.
   PubMed Web of Science ®Google Scholar
• Park SG, Kim Y, Park E, Ryu HM, Jung G. Fidelity of hepati-tis B virus polymerase. Eur J Biochem. 2003;270(14):2929–2936.
   PubMedGoogle Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hep-atitis B. N Engl J Med. 2003;348(9):808–816.
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of ente-cavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–1010.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predic-tor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–1897.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLach-lan A. Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication inter-mediates and nuclear covalently closed circular hepa-titis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice. J Virol. 2005;79(17):11045–11052.
   PubMed Web of Science ®Google Scholar